Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05062486 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Efficacy of RQC for AMD
A Phase 2 study of Age-related Macular Degeneration, sponsored by Paul A Knepper, MD PhD.
- Completed
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
- 1
- Study location
NCT05062486: Completed Phase 2 study of Age-related Macular Degeneration, sponsored by Paul A Knepper, MD PhD.
NCT05062486 is a Phase 2 study of Age-related Macular Degeneration that has completed, run by Paul A Knepper, MD PhD. The registered enrollment target is 55 participants, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05062486, a Phase 2 study of Age-related Macular Degeneration, has completed, sponsored by Paul A Knepper, MD PhD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the safety and efficacy of resveratrol, quercetin, and curcumin in combination (RQC) over 2 years in patients with age-related macular degeneration (AMD).
Primary Outcome
Macular drusen volume measured in µm3.
Conditions Studied
Interventions
- DRUG Curcumin
- DRUG Resveratrol, Quercetin, Curcumin (RQC)
Study Locations (1)
Illinois
- Zaparackas M.D. & Knepper M.D. Ph.D., Ltd - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2021-10-04 |
| Est. Completion | 2024-11-07 |
| Phase | Phase 2 |
What the finished NCT05062486 record still lists
NCT05062486 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 2 interventions - of which Curcumin is the first listed.
NCT05062486 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT05062486 about?
NCT05062486 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of RQC for AMD". To evaluate the safety and efficacy of resveratrol, quercetin, and curcumin in combination (RQC) over 2 years in patients with age-related macular degeneration (AMD).
What is the current status of trial NCT05062486?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2021-10-04. Estimated completion is 2024-11-07.
What conditions does trial NCT05062486 study?
This clinical trial studies the following conditions: Age-related Macular Degeneration.
What interventions are being tested in trial NCT05062486?
The interventions under investigation include: Curcumin (DRUG), Resveratrol, Quercetin, Curcumin (RQC) (DRUG).
Who is sponsoring clinical trial NCT05062486?
This trial is sponsored by Paul A Knepper, MD PhD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05062486 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05062486's enrollment target sits among peer trials
55 46th of 74 higher than 29 of 74 other Age-related Macular Degeneration trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Age-related Macular Degeneration trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dark Adaptation as an Early Indicator of Response to Statin Therapy for Intermediate AMD
RECRUITING · Phase 2
-
A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration
ACTIVE NOT RECRUITING · Phase 2
-
Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
COMPLETED · Phase 2
-
ReCLAIM-2 Study to Evaluate Safety,Efficacy & Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GA
COMPLETED · Phase 2
-
Retinal and Retinal Pigment Epithelium (RPE) Autoimmunity in Age-related Macular Degeneration (AMD)
COMPLETED · Phase 2
-
Triple Therapy - PDT Plus IVD and Intravitreal Ranibizumab Versus Lucentis Monotherapy to Treat Age-Related Macular Degeneration
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI